Finanzen von Odyssey Therapeutics Inc (ODTX)ODTXOdyssey Therapeutics Inc

In the context of the broader market, ODTX competes directly with industry leaders such as SGP and JBIO. With a market capitalization of $869.86M, it holds a significant position in the sector. When comparing efficiency, ODTX's gross margin of N/A stands against SGP's N/A and JBIO's N/A. Such benchmarking helps identify whether Odyssey Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a net loss of $52.8 million in Q2 2026, an increase from $41.2 million in the same quarter last year, reflecting rising R&D expenses.